Now Available: Medtech Insight’s Top 100 Ranking Of Companies By Sales And 2021 Outlook
The leading publicly-owned global cardiology, orthopedic, IVD and imaging companies listed alongside the global top 100
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
You may also be interested in...
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Evolving health care demands, digital innovation and the need to work within tighter budgets have prompted the UK’s NICE to reset its strategy for the coming five years.